NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 253)
Posted On: 02/01/2023 4:28:35 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol amendment to its ongoing CYB004-E phase 1 trial. The approval came from an independent ethics committee in the Netherlands. The first-ever trial that evaluates deuterated DMT in humans, the study is being conducted at the Centre for Human Drug Research in the Netherlands; it is the largest-ever Phase 1 DMT trial conducted to date. Based on previous studies, CYB004 has shown potential to deliver an improved bioavailability and pharmacokinetic profile in comparison to DMT when administered via intravenous and inhaled routes, as well as deliver a longer duration of effect and offer more convenient dosing methods through inhaled, subcutaneous or intramuscular routes of administration. “This is a major milestone for our CYB004 program and for better understanding the potential therapeutic benefits of our proprietary deuterated DMT molecule for the treatment of generalized anxiety disorder,” said Cybin CEO Doug Drysdale in the press release. “The ability to evaluate our novel CYB004 molecule in humans at this early stage is a significant achievement in clinical development and will provide important insight into the pharmacokinetic and pharmacodynamic properties of CYB004 in addition to what we have already learned through our study of DMT. We expect to apply these findings to optimize dosing and delivery of CYB004 in future clinical trials, which supports our mission to bring this new investigational therapy to patients as quickly as possible.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol amendment to its ongoing CYB004-E phase 1 trial. The approval came from an independent ethics committee in the Netherlands. The first-ever trial that evaluates deuterated DMT in humans, the study is being conducted at the Centre for Human Drug Research in the Netherlands; it is the largest-ever Phase 1 DMT trial conducted to date. Based on previous studies, CYB004 has shown potential to deliver an improved bioavailability and pharmacokinetic profile in comparison to DMT when administered via intravenous and inhaled routes, as well as deliver a longer duration of effect and offer more convenient dosing methods through inhaled, subcutaneous or intramuscular routes of administration. “This is a major milestone for our CYB004 program and for better understanding the potential therapeutic benefits of our proprietary deuterated DMT molecule for the treatment of generalized anxiety disorder,” said Cybin CEO Doug Drysdale in the press release. “The ability to evaluate our novel CYB004 molecule in humans at this early stage is a significant achievement in clinical development and will provide important insight into the pharmacokinetic and pharmacodynamic properties of CYB004 in addition to what we have already learned through our study of DMT. We expect to apply these findings to optimize dosing and delivery of CYB004 in future clinical trials, which supports our mission to bring this new investigational therapy to patients as quickly as possible.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)